220 related articles for article (PubMed ID: 32505062)
1. Predictive factors for high-grade transformation in benign meningiomas.
Kwon SM; Kim JH; Yoo HJ; Kim YH; Hong SH; Cho YH; Kim CJ; Nam SJ
Clin Neurol Neurosurg; 2020 Aug; 195():105897. PubMed ID: 32505062
[TBL] [Abstract][Full Text] [Related]
2. Clinicoradiological Features of Recurrent Meningioma With High Grade Transformation.
Yeon EK; Sung JY; DO SI; Park BJ; Kim EJ; Na K
Anticancer Res; 2019 Nov; 39(11):6299-6305. PubMed ID: 31704860
[TBL] [Abstract][Full Text] [Related]
3. Clinical Implications of the Mitotic Index as a Predictive Factor for Malignant Transformation of Atypical Meningiomas.
Kwon SM; Kim JH; Kim YH; Hong SH; Cho YH; Kim CJ; Nam SJ
J Korean Neurosurg Soc; 2022 Mar; 65(2):297-306. PubMed ID: 34879641
[TBL] [Abstract][Full Text] [Related]
4. Benign versus atypical meningiomas: risk factors predicting recurrence.
Nowak A; Dziedzic T; Krych P; Czernicki T; Kunert P; Marchel A
Neurol Neurochir Pol; 2015; 49(1):1-10. PubMed ID: 25666766
[TBL] [Abstract][Full Text] [Related]
5. Histopathology and MIB-1 labeling index predicted recurrence of meningiomas: a proposal of diagnostic criteria for patients with atypical meningioma.
Ho DM; Hsu CY; Ting LT; Chiang H
Cancer; 2002 Mar; 94(5):1538-47. PubMed ID: 11920512
[TBL] [Abstract][Full Text] [Related]
6. Noninvasive evaluation of the malignant potential of intracranial meningiomas performed using proton magnetic resonance spectroscopy.
Shino A; Nakasu S; Matsuda M; Handa J; Morikawa S; Inubushi T
J Neurosurg; 1999 Dec; 91(6):928-34. PubMed ID: 10584837
[TBL] [Abstract][Full Text] [Related]
7. Recurrence and regrowth of benign meningiomas.
Nakasu S; Fukami T; Jito J; Nozaki K
Brain Tumor Pathol; 2009; 26(2):69-72. PubMed ID: 19856217
[TBL] [Abstract][Full Text] [Related]
8. Resected WHO grade I meningioma and predictors of local control.
Nowak-Choi K; Palmer JD; Casey J; Chitale A; Kalchman I; Buss E; Keith SW; Hegarty SE; Curtis M; Solomides C; Shi W; Judy K; Andrews DW; Farrell C; Werner-Wasik M
J Neurooncol; 2021 Mar; 152(1):145-151. PubMed ID: 33420897
[TBL] [Abstract][Full Text] [Related]
9. Analysis of the results of recurrent intracranial meningiomas treated with re-radiosurgery.
Kim M; Lee DH; Kim Rn HJ; Cho YH; Kim JH; Kwon DH
Clin Neurol Neurosurg; 2017 Feb; 153():93-101. PubMed ID: 28081463
[TBL] [Abstract][Full Text] [Related]
10. Histopathological prognostic factors of recurrence following definitive therapy for atypical and malignant meningiomas.
Kim D; Niemierko A; Hwang WL; Stemmer-Rachamimov AO; Curry WT; Barker FG; Martuza RL; Oh KS; Loeffler JS; Shih HA
J Neurosurg; 2018 Apr; 128(4):1123-1132. PubMed ID: 28621619
[TBL] [Abstract][Full Text] [Related]
11. WHO grade of intracranial meningiomas differs with respect to patient's age, location, tumor size and peritumoral edema.
Ressel A; Fichte S; Brodhun M; Rosahl SK; Gerlach R
J Neurooncol; 2019 Nov; 145(2):277-286. PubMed ID: 31578671
[TBL] [Abstract][Full Text] [Related]
12. Ki-67 proliferative index predicts clinical outcome in patients with atypical or anaplastic meningioma.
Bruna J; Brell M; Ferrer I; Gimenez-Bonafe P; Tortosa A
Neuropathology; 2007 Apr; 27(2):114-20. PubMed ID: 17494511
[TBL] [Abstract][Full Text] [Related]
13. Brain invasion assessability in meningiomas is related to meningioma size and grade, and can be improved by extensive sampling of the surgically removed meningioma specimen.
Pizem J; Velnar T; Prestor B; Mlakar J; Popovic M
Clin Neuropathol; 2014; 33(5):354-63. PubMed ID: 25034703
[TBL] [Abstract][Full Text] [Related]
14. DNA topoisomerase II-alpha and cyclin A immunoexpression in meningiomas and its prognostic significance: an analysis of 263 cases.
Korshunov A; Shishkina L; Golanov A
Arch Pathol Lab Med; 2002 Sep; 126(9):1079-86. PubMed ID: 12204057
[TBL] [Abstract][Full Text] [Related]
15. Benign spinal meningioma without dural attachment presenting delayed CSF dissemination and malignant transformation.
Tsuda K; Akutsu H; Yamamoto T; Ishikawa E; Saito A; Nakai K; Takano S; Matsumura A
Brain Tumor Pathol; 2013 Jul; 30(3):185-91. PubMed ID: 22915133
[TBL] [Abstract][Full Text] [Related]
16. Stereotactic radiation treatment for recurrent nonbenign meningiomas.
Mattozo CA; De Salles AA; Klement IA; Gorgulho A; McArthur D; Ford JM; Agazaryan N; Kelly DF; Selch MT
J Neurosurg; 2007 May; 106(5):846-54. PubMed ID: 17542529
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcomes of fractionated stereotactic radiotherapy for intracranial skull base benign meningiomas in single institution.
Onodera S; Aoyama H; Katoh N; Taguchi H; Yasuda K; Yoshida D; Surtherland K; Suzuki R; Ishikawa M; Gerard B; Terasaka S; Shirato H
Jpn J Clin Oncol; 2011 Apr; 41(4):462-8. PubMed ID: 21177777
[TBL] [Abstract][Full Text] [Related]
18. Necrosis is a consistent factor to recurrence of meningiomas: should it be a stand-alone grading criterion for grade II meningioma?
Góes P; Santos BFO; Suzuki FS; Salles D; Stávale JN; Cavalheiro S; de Paiva Neto MA
J Neurooncol; 2018 Apr; 137(2):331-336. PubMed ID: 29270884
[TBL] [Abstract][Full Text] [Related]
19. Risk Factors for High-Grade Meningioma in Brain and Spine: Systematic Review and Meta-analysis.
Shin HK; Park JH; Cho YH; Kim YH; Hong SH; Kim JH; Roh SW; Jeon SR
World Neurosurg; 2021 Jul; 151():e718-e730. PubMed ID: 33974984
[TBL] [Abstract][Full Text] [Related]
20. Benign meningiomas (WHO Grade I) with atypical histological features: correlation of histopathological features with clinical outcomes.
Marciscano AE; Stemmer-Rachamimov AO; Niemierko A; Larvie M; Curry WT; Barker FG; Martuza RL; McGuone D; Oh KS; Loeffler JS; Shih HA
J Neurosurg; 2016 Jan; 124(1):106-14. PubMed ID: 26274991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
